Refine by
Biopsy Tissue Articles & Analysis
15 news found
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
ByCELLINK
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
Koios Medical, Inc has received 510(k) clearance from the U.S. Food and Drug Administration for Koios DS (Decision Support) Breast 2.0, a new version of its machine learning based platform that assists physicians in the classification and diagnosis of breast cancer. The software offers a proprietary alignment to BI-RADS® for any lesion analyzed and is available connected to PACS and/or ...
BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive ...
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, SuppresSTEM which included Crown ...
A new biopsy sheath developed by Raleigh med tech startup UVision360 is ready to hit the market after landing federal approval this week. UVision360 announced it had received the greenlight from the U.S. Food and Drug Administration for its patented LUMINELLE 360° Bx Sheath. The device expands the startup’s “all-in-one” gynecological system LUMINELLE DTx, an endoscopic ...
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible ...
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and ...
UVision360, Inc., an innovative medical device company, announces today that the U.S. Food and Drug Administration (FDA) has approved the patented LUMINELLE 360° Bx (Biopsy) Sheath which expands the capability of the LUMINELLE® DTx System. The LUMINELLE 360° Bx sheath, combined with the LUMINELLE DTx System, is the first and only integrated directed biopsy device not requiring ...
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, and researchers at the Karolinska Institutet (Stockholm, Sweden), led by Dr. Ulf Hedin, announced ...
ByElucid
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...
NanoPin Technologies, Inc., whose mission is to develop advanced diagnostics to improve the lives of millions of individuals affected by infectious disease, announces the formation of a collaboration with Thermo Fisher Scientific to refine the liquid chromatography mass spectrometry (LCMS)-based workflow to allow robust and highly sensitive clinical application of NanoPin’s proprietary ...
CrossBay Medical, Inc., today announced that it has received clearance to commercialize its product, the Endometrial Tissue Sampler using CrossGlide™ technology, in Europe by obtaining its CE Mark. The use of this technology allows a novel way to obtain an office-based endometrial biopsy, a very common tissue-sampling procedure performed in women’s health offices worldwide. The ETS is ...
NEWPORT BEACH, Calif.– July 24, 2019– oVio Technologies, Inc., a leader in the creation of biometric dimensional imagery technologies, recently partnered with AVRA Medical Robotics, Inc. (OTCQB: AVMR), a leading innovator of medical robotic solutions, to spur autonomous robotic development in the medical industry. AVRA will utilize oVio’s imaging technology to assist in the ...
The University of Arizona has licensed the design for a next-generation needle biopsy instrument that utilizes electrosurgery and electrocautery to safely increase tissue sample volumes in minimally invasive biopsy procedures. The licensee is a startup company, Data Driven Diagnostics Sciences Inc., also known as D3Sciences, or D3S. The inventing team includes Dr. Michael Larson, resident ...